Dalbeth, Nicola
Choi, Hyon K.
Joosten, Leo A. B.
Khanna, Puja P.
Matsuo, Hirotaka
Perez-Ruiz, Fernando
Stamp, Lisa K.
Article History
Accepted: 6 August 2019
First Online: 26 September 2019
Competing interests
: N.D. has received speaking fees from Pfizer, Horizon, Janssen and AbbVie; consulting fees from Horizon, Hengrui and Kowa; and research funding from Amgen and AstraZeneca; and is currently principal investigator on a clinical trial of intensive urate-lowering therapy (funded by the Health Research Council of New Zealand). Within the past 5 years, N.D. has been principal investigator on a clinical trial of febuxostat in early gout, and received consulting or speaking fees from Takeda, Menarini and Teijin. H.K.C. received research support from AstraZeneca and consulting fees from Takeda, Selecta, GSK and Horizon. L.A.B.J. has received a speaking fee from Novartis, research funding from Ardea Biosciences/AstraZeneca, and is Scientific Advisory Board member of Olatec Therapeutics LLC. P.P.K. has received research grants from Ironwood, Sobi and Horizon. F.P.-R. has been an advisor for Amgen, Horizon, GrĂ¼nenthal, Menarini, Sanofi and Syneos-Health; a speaker for Amgen, Astellas, GrĂ¼nenthal, Lilly, Logarithm, Menarini and the Spanish Foundation for Rheumatology; received investigation grants from Cruces Rheumatology Association and the Spanish Foundation for Rheumatology; and received congress funding from Lilly, Novartis and the European League Against Rheumatism (EULAR). L.K.S. has received speaking fees from Amgen and is currently principal investigator on a clinical trial of colchicine prophylaxis (funded by the Health Research Council of New Zealand). L.K.S. is a member of the Medicines Adverse Reaction Committee of New Zealand and the New Zealand Pharmaceutical Management Agency (PHARMAC) Rheumatology Subcommittee. H.M. declares no competing interests.